5 Key Takeaways

• 1

  Patient selection for Encelto treatment in MacTel focuses on younger patients with smaller lesions and some degree of photoreceptor loss.

• 2

  Early intervention is crucial, as patients with early-stage MacTel may benefit most from the FDA-approved treatment.

• 3

  The treatment aims to preserve vision by protecting viable photoreceptors, often prioritizing the better-seeing eye.

• 4

  Post-treatment follow-up includes regular assessments every six months to monitor disease progression and implant site health.

• 5

  Coordination of care between specialists and referring ophthalmologists is essential for managing MacTel patients effectively.